References
- Black W, Vasiliou V. The aldehyde dehydrogenase gene superfamily resource center. Hum Genomics 2009;4:136–142.
- Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985;230:181–183.
- Maring JA, Deitrich RA, Little R. Partial purification and properties of human brain aldehyde dehydrogenases. J Neurochem 1985;45:1903–1910.
- Choudhary S, Xiao T, Srivastava S, Zhang W, Chan LL, Vergara LA et al. Toxicity and detoxification of lipid-derived aldehydes in cultured retinal pigmented epithelial cells. Toxicol Appl Pharmacol 2005;204:122–134.
- Zhang M, Shoeb M, Goswamy J, Liu P, Xiao TL, Hogan D et al. Overexpression of aldehyde dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res 2010;88:686–694.
- Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G et al. Gene expression profiling of sporadic Parkinson’s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005;1053:356–375.
- Galter D, Buervenich S, Carmine A, Anvret M, Olson L. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson’s disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis 2003;14:637–647.
- Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci 2008;6:8.
- MacKerell AD Jr, Pietruszko R. Chemical modification of human aldehyde dehydrogenase by physiological substrate. Biochim Biophys Acta 1987;911:306–317.
- Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008;321:1493–1495.
- Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008;115:193–203.
- Moore SA, Baker HM, Blythe TJ, Kitson KE, Kitson TM, Baker EN. Sheep liver cytosolic aldehyde dehydrogenase: the structure reveals the basis for the retinal specificity of class 1 aldehyde dehydrogenases. Structure 1998;6:1541–1551.
- Perez-Miller S, Younus H, Vanam R, Chen CH, Mochly-Rosen D, Hurley TD. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat Struct Mol Biol 2010;17:159–164.
- Zhou W, Calciano MA, Jordan H, Brenner M, Johnson S, Wu D et al. High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity. BMC Genet 2009;10:63.
- Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315–3321.
- Life Chemicals Inc., Burlington, Canada.
- Lazaridis T, Masunov A, Gandolfo F. Contributions to the binding free energy of ligands to avidin and streptavidin. Proteins 2002;47:194–208.
- Arolfo MP, Overstreet DH, Yao L, Fan P, Lawrence AJ, Tao G et al. Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcohol Clin Exp Res 2009;33:1935–1944.
- Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J et al. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med 2007;13:695–702.
- Yao L, Fan P, Arolfo M, Jiang Z, Olive MF, Zablocki J et al. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis. Nat Med 2010;16:1024–1028.
- Eaton P, Li JM, Hearse DJ, Shattock MJ. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol 1999;276:H935–H943.